Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12^th, 2023 at 2:00 p.m. Pacific Time.

The presentation will be webcast and can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.

About Innoviva

Innoviva, Inc., is a diversified holding company with a portfolio of royalties and other healthcare assets, including Innoviva Specialty Therapeutics, a subsidiary focused on delivering innovative therapies in critical care and infectious disease. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. ANORO, RELVAR and BREO are trademarks of the GSK group of companies. For more information on Innoviva, please visit here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005949/en/

The Innoviva Stock at the time of publication of the news with a fall of -0,91 % to 13,08EUR on Nasdaq stock exchange (06. Juni 2023, 21:55 Uhr).